RT Journal Article
SR Electronic
T1 Evaluating SARS-CoV-2 spike and nucleocapsid proteins as targets for IgG antibody detection in severe and mild COVID-19 cases using a Luminex bead-based assay
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.25.20161943
DO 10.1101/2020.07.25.20161943
A1 Mariën, Joachim
A1 Michiels, Johan
A1 Heyndrickx, Leo
A1 Kerkhof, Karen
A1 Foque, Nikki
A1 Widdowson, Marc-Alain
A1 Desombere, Isabelle
A1 Jansens, Hilde
A1 Van Esbroeck, Marjan
A1 Ariën, Kevin K.
YR 2020
UL http://medrxiv.org/content/early/2020/07/27/2020.07.25.20161943.abstract
AB Large-scale serosurveillance of severe acute respiratory syndrome coronavirus type 2 (SARS- CoV-2) will only be possible if serological tests are sufficiently reliable, rapid and inexpensive. Current assays are either labour-intensive and require specialised facilities (e.g. virus neutralization assays), or expensive with suboptimal specificity (e.g. commercial ELISAs). Bead-based assays offer a cost-effective alternative and allow for multiplexing to test for antibodies of other pathogens. Here, we compare the performance of four antigens for the detection of SARS-CoV-2 specific IgG antibodies in a panel of sera that includes both severe (n=40) and mild (n=52) cases, using a neutralization and a Luminex bead-based assay. While we show that neutralising antibody levels are significantly lower in mild than in severe cases, we demonstrate that a combination of recombinant nucleocapsid protein (NP), receptor- binding domain (RBD) and the whole spike protein (S1S2) results in a highly sensitive (96%) and specific (99%) bead-based assay that can detect IgG antibodies in both groups. Although S1-specific IgG levels correlate most strongly with neutralizing antibody levels, they fall below the detection threshold in 10% of the cases in our Luminex assay. In conclusion, our data supports the use of RBD, NP and S1S2 for the development of SARS-CoV-2 serological bead- based assays. Finally, we argue that low antibody levels in mild/asymptomatic cases might complicate the epidemiological assessment of large-scale surveillance studies.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is not a clinical trailFunding StatementThe work was funded by a European & Developing Countries Clinical Trials Partnership (EDCTP) project (Africover: RIA2020EF-3031), the Research Foundation Flanders (FWO) (G0G4229N and G054820N) and intramural funds from the Institute of Tropical Medicine Antwerp. Joachim Marien is a member of the Outbreak Research Team which is funded by the Department of Economy, Science and Innovation of the Flemish government in Belgium (EE145 4150).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval to sample from COVID-19 cases was obtained from the Ethical committee of the University of Ghent (BC-07587), local committees of each participating hospital and all participants provided consent to participate. The use of prepandemic leftover samples was approved by ITMs internal review board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData supporting the conclusions of this article are included in the article and its additional files. The datasets used and/or analysed during the current study are available from the corresponding author upon reasonable request.